about
ACE Inhibitor PathwayMultilevel analysis of systolic blood pressure and ACE gene I/D polymorphism in 438 Swedish families--a public health perspective.The Finnish Cardiovascular Study (FINCAVAS): characterising patients with high risk of cardiovascular morbidity and mortality.Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonancePharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine.Complex haplotypes derived from noncoding polymorphisms of the intronless alpha2A-adrenergic gene diversify receptor expression.Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review.Pharmacogenetics in drug regulation: promise, potential and pitfalls.Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate.Genetic variations of tubular sodium reabsorption leading to "primary" hypertension: from gene polymorphism to clinical symptoms.Can pharmacogenetics help rescue drugs withdrawn from the market?An overview of ethnicity and assessment of family history in primary care settings.Phase I and Phase II enzyme polymorphisms and childhood cancer.Personalized medicine for high blood pressure.Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker.CYP3A5 polymorphism, amlodipine and hypertension.Alopecia and ocular alterations: a role for Minoxidil?Endothelial nitric oxide synthase (eNOS) variants in cardiovascular disease: pharmacogenomic implications.Randomized, double-blinded trial evaluation of valsartan/hydrochlorothiazide combination therapy in mild to moderate essential hypertension in north-east China.Pharmacogenomics and antihypertensive drugs: a path toward personalized medicineRenin Angiotensin Aldosterone System (RAAS)
P2860
Q29892242-786E6FA6-864F-40AC-8074-90BBD7F3470EQ30809927-42840496-898A-47EA-B4CC-F7EE0AD083D3Q33235420-F8E4970A-31F3-4D2D-B579-5BC97ADCC89CQ33776918-2BC0EA75-176D-47B8-9558-EA9542CF5A83Q34485100-4854229D-C778-454F-8143-09A200B55A64Q34600291-E1FAAFF7-CAC5-473F-9621-9C25EC8307E4Q34747512-2A721E5C-ECA3-4DA4-BCF9-D9C61DC2E323Q35038052-4745B132-8410-4055-8FBB-323933C18676Q35049590-228174FE-89AA-41C2-B110-FEF39CF547FDQ36309653-A639E3F1-4A07-4AF0-9182-C3310B712DA2Q36596713-B0143166-86C9-44FB-AE95-A60672B5B719Q36603269-9E8B95F7-68FB-4264-A6C2-C41FADB91260Q36668333-F202FAE4-D637-4EEA-9D16-652DAB019D49Q36807180-B96317AA-6751-4CA4-A69D-7ACB0DEDE270Q37033656-74EBD7F9-9FA6-43F7-9102-527876906C77Q38122295-C4722262-AF82-468F-B150-435B1E9ED979Q39711424-CD115BEF-B05A-4225-8F07-1EC3CB2AC968Q41854943-CFA17748-71C6-4556-9DFE-965171734E0AQ46464310-253EFAF3-A253-4B86-93D9-C222842AC8D1Q57995102-C304B5BD-9FAE-447A-A2D4-264F11E9D99AQ84973975-6CF0DE83-4619-4963-981D-DDF89563622E
P2860
description
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2004
@ast
scientific journal article
@en
vedecký článok (publikovaný 2004/01/01)
@sk
vědecký článek publikovaný v roce 2004
@cs
wetenschappelijk artikel (gepubliceerd op 2004/01/01)
@nl
наукова стаття, опублікована в січні 2004
@uk
مقالة علمية (نشرت عام 2004)
@ar
name
Pharmacogenetics of antihypertensive drug responses
@ast
Pharmacogenetics of antihypertensive drug responses
@en
Pharmacogenetics of antihypertensive drug responses
@nl
type
label
Pharmacogenetics of antihypertensive drug responses
@ast
Pharmacogenetics of antihypertensive drug responses
@en
Pharmacogenetics of antihypertensive drug responses
@nl
prefLabel
Pharmacogenetics of antihypertensive drug responses
@ast
Pharmacogenetics of antihypertensive drug responses
@en
Pharmacogenetics of antihypertensive drug responses
@nl
P1476
Pharmacogenetics of antihypertensive drug responses
@en
P2093
Gary L. Schwartz
Stephen T. Turner
P304
P356
10.2165/00129785-200404030-00002
P577
2004-01-01T00:00:00Z
P6179
1050010352